Featured post

SCS research and awards news

For all our research and awards news, please visit our news page.

Monday 26 March 2018

Post-Doctoral Fellow : Human T lymphocyte/ CAR-T cells: Cartherics Pty Ltd

Position Description: Cartherics is seeking a talented Post-Doctoral Fellow to help implement its very active research program in Chimeric Antigen Receptor (CAR) -T based immunotherapies.

CAR-T cells have rapidly evolved as a revolution in anti-cancer treatments. Cartherics primary platform is to use induced pluripotential stem cells (iPSC) to embed a TCR specificity. These T-iPSC will then be gene edited with specific CAR’s, and induced to differentiate into cytotoxic T cells. Central to the success of these platforms will be to maximise T cell expansion and differentiation in sufficient effective numbers for clinical trials. This project will explore the forward reprograming of iPSCs using transcription factors to induce T cell differentiation and to optimise their function. The successful applicant will thus have a strong background in immunology related tissue culture and a preference for experience preferably with human iPSCs and/or T cells. They will have a desire to succeed in a competitive environment and relish the challenge of helping to implement new technologies and equipment as necessary; the rewards will be substantial. Accordingly, the successful applicant will have extensive experience in immunology-based research techniques.

Education/Qualifications: The appointee will either have a PhD or experience as a research assistant, in a relevant field preferably including iPSCs from a recognised university or research institute. They will be working within a dynamic team but as a Post-Doctoral appointment, they will be expected to contribute in a leadership capacity. Company Description Cartherics Pty Ltd is an exciting new Melbourne-based start-up biotechnology company, developing the next generation immune therapeutic approach to treat cancer. The Company’s objective is to identify and expand T cells with their own cancer recognizing T Cell Receptors (TCRs), then use sophisticated gene editing to empower these cells with additional cancer-specific recognition and activation molecules (CAR-T). Cartherics will use stem cell technology to exponentially expand these “cancer smart” killer cells.

The laboratories are located within the new facilities of the Monash Health Translation Precinct at Monash Medical Centre, Clayton, Vic 3168. Send application with CV including potential referees to: Karen Loudon Karen.loudon@hudson.org.au

Closing date 15 April 2018.

No comments:

Post a Comment